Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Subscribe To Our Newsletter & Stay Updated
